Skip to main content
. 2021 Jun 17;10(2):539–555. doi: 10.1007/s40120-021-00260-5

Fig. 3.

Fig. 3

Expert opinion on starting a new disease-modifying therapy (Question 1, solid bars) or continuing an existing DMT therapy (Question 2, hatched bars) for a patient with multiple sclerosis. GA glatiramer acetate